Paul Loubet1, Nezha Samih-Lenzi2, Florence Galtier3, Philippe Vanhems4, Pierre Loulergue5, Xavier Duval6, Stéphane Jouneau7, Déborah Postil8, Sylvie Rogez9, Martine Valette10, Corinne Merle11, Corinne Régis12, Yolande Costa13, Zineb Lesieur2, Pierre Tattevin14, Bruno Lina10, Fabrice Carrat15, Odile Launay16. 1. Inserm, CIC 1417, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Infectious Diseases, CIC Cochin Pasteur, Cochin Broca Hôtel-Dieu hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. 2. Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France. 3. CHRU de Montpellier, CIC 1411, Hôpital Saint-Eloi, Montpellier, France. 4. Service d'Hygiène, Epidémiologie et Prévention, Groupement Hospitalier Edouard Herriot, Lyon, France; Emerging Pathogens Laboratory - Fondation Mérieux, Centre International de Recherche en Infectiologie (CIRI) Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, 21, Avenue Tony Garnier, Lyon 69007, France. 5. Inserm, CIC 1417, Paris, France; Department of Infectious Diseases, CIC Cochin Pasteur, Cochin Broca Hôtel-Dieu hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France. 6. Inserm CIC 1425, Hôpital Bichat-Claude Bernard, APHP, Paris, France; IAME UMR 1137, Univ Paris Diderot, Sorbonne Paris Cité, F-75019 Paris, France. 7. Centre Hospitalo-Universitaire de Rennes, Service de Pneumologie, IRSET UMR 1085, Université de Rennes 1, Rennes, France. 8. CHU Dupuytren, CIC 1435, Limoge Cedex, France. 9. CHU Dupuytren, Service Bactériologie, Virologie, Hygiène, Limoges Cedex, France. 10. CNR Virus Influenza, Hospices Civils de Lyon, Bron, University of Lyon, Lyon, France. 11. CHRU de Montpellier, Service de Maladies Infectieuses et Tropicales, Hôpital Saint-Eloi, Montpellier, France. 12. Université Lyon 1, Laboratoire de Biométrie et Biologie Evolutive, UMR CNRS 5558, France, France. 13. Inserm CIC 1425, Hôpital Bichat-Claude Bernard, APHP, Paris, France. 14. CHRU de Rennes, Service de Maladies Infectieuses et Tropicales, Rennes, France. 15. Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), F75012, Paris, France; Public health department, Hopital Saint-Antoine, APHP, Paris, France. 16. Inserm, CIC 1417, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Infectious Diseases, CIC Cochin Pasteur, Cochin Broca Hôtel-Dieu hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Inserm, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France. Electronic address: odile.launay@cch.aphp.fr.
Abstract
BACKGROUND: Influenza is an important cause of serious illness and death, particularly in elderly and high-risk groups. OBJECTIVES: Aim of this study was to identify factors associated with poor outcomes among adults hospitalized in France for laboratory-confirmed seasonal influenza. STUDY DESIGN: Patients hospitalized for influenza were identified in a prospective, multicenter study carried out in French hospitals during three consecutive influenza seasons (2012-2015). Influenza virus infection was confirmed by reverse transcription polymerase chain reaction. Sociodemographic and clinical variables were compared according to the virus type and subtype. Risk factors for complications, intensive care unit (ICU) admission and death were analyzed by backward stepwise logistic regression. RESULTS: The study population consisted of 566 patients, of whom 56% were older than 65 years and 82% had underlying chronic illnesses. Type A influenza viruses infected 422 patients (75%), including subtype H3N2 in 239 patients (57%). The prior vaccine coverage rate was 38%. Complications occurred in 255 patients (45%), consisting mainly of pneumonia (n=143, 30%) and respiratory failure (n=116, 20%). Eighty-three patients (15%) were admitted to an ICU, and the in-hospital mortality rate was 4% (n=21). Sixty-six patients (12%) received oseltamivir. Age over 65 years was the only identified risk factor for complications. Risk factors for ICU admission were an absence of vaccination, no oseltamivir administration before admission, pre-existing chronic respiratory disease, and current smoking. Age over 65 years and ICU admission were risk factors for death. CONCLUSIONS: Older individuals and patients with underlying conditions are most at risk of influenza complications. Vaccination and early oseltamivir administration, both of which are recommended for these patients, appear to reduce ICU admissions.
BACKGROUND:Influenza is an important cause of serious illness and death, particularly in elderly and high-risk groups. OBJECTIVES: Aim of this study was to identify factors associated with poor outcomes among adults hospitalized in France for laboratory-confirmed seasonal influenza. STUDY DESIGN:Patients hospitalized for influenza were identified in a prospective, multicenter study carried out in French hospitals during three consecutive influenza seasons (2012-2015). Influenzavirus infection was confirmed by reverse transcription polymerase chain reaction. Sociodemographic and clinical variables were compared according to the virus type and subtype. Risk factors for complications, intensive care unit (ICU) admission and death were analyzed by backward stepwise logistic regression. RESULTS: The study population consisted of 566 patients, of whom 56% were older than 65 years and 82% had underlying chronic illnesses. Type A influenza viruses infected 422 patients (75%), including subtype H3N2 in 239 patients (57%). The prior vaccine coverage rate was 38%. Complications occurred in 255 patients (45%), consisting mainly of pneumonia (n=143, 30%) and respiratory failure (n=116, 20%). Eighty-three patients (15%) were admitted to an ICU, and the in-hospital mortality rate was 4% (n=21). Sixty-six patients (12%) received oseltamivir. Age over 65 years was the only identified risk factor for complications. Risk factors for ICU admission were an absence of vaccination, no oseltamivir administration before admission, pre-existing chronic respiratory disease, and current smoking. Age over 65 years and ICU admission were risk factors for death. CONCLUSIONS: Older individuals and patients with underlying conditions are most at risk of influenza complications. Vaccination and early oseltamivir administration, both of which are recommended for these patients, appear to reduce ICU admissions.
Authors: Shekhar Ghamande; Courtney Shaver; Kempapura Murthy; Chandni Raiyani; Heath D White; Tasnim Lat; Alejandro C Arroliga; Dayna Wyatt; H Keipp Talbot; Emily T Martin; Arnold S Monto; Richard K Zimmerman; Donald B Middleton; Fernanda P Silveira; Jill M Ferdinands; Manish M Patel; Manjusha Gaglani Journal: Clin Infect Dis Date: 2022-04-28 Impact factor: 20.999
Authors: Sara P H van den Berg; Albert Wong; Marion Hendriks; Ronald H J Jacobi; Debbie van Baarle; Josine van Beek Journal: Front Immunol Date: 2018-01-29 Impact factor: 7.561
Authors: Dominic E Dwyer; Ruth Lynfield; Marcelo H Losso; Richard T Davey; Alessandro Cozzi-Lepri; Deborah Wentworth; Timothy M Uyeki; Fred Gordin; Brian Angus; Tavs Qvist; Sean Emery; Jens Lundgren; James D Neaton Journal: Open Forum Infect Dis Date: 2017-10-07 Impact factor: 3.835
Authors: Kathryn B Anderson; Sriluck Simasathien; Veerachai Watanaveeradej; Alden L Weg; Damon W Ellison; Detchvijitr Suwanpakdee; Chonticha Klungthong; Thipwipha Phonpakobsin; Phirangkul Kerdpanich; Danabhand Phiboonbanakit; Robert V Gibbons; Stefan Fernandez; Louis R Macareo; In-Kyu Yoon; Richard G Jarman Journal: PLoS One Date: 2018-03-07 Impact factor: 3.240